Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 373 participants.

Also called NCT01364428

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 373 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01364428
  • WHO UTN U1111-1119-2518
Other papers using this trial's data
  • Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare) Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2014-08 DOI, PubMed 24518180

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01364428. Randomized; no masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-01 (actual). Results posted on 2015-11-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus
Acronym
BEGIN™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec
Intervention (Drug)
insulin degludec
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01364428
Content hash
a3d77ade7b9f4f6d386c769acc453cbf72ee554b9427885b1f2e0bd3697e6eb8